Vendor dossier · Chengdu
Flourishglobal Peptide Biotech (Chengdu) Co., Ltd.
A Chengdu operation that answers correspondence faster than anyone in the directory and tests less than most.
Journal grade · ranked 8 of 20
799 reader reports
on the record
FGP replies to email in hours, sends photographs of the actual vials before dispatch, and will hold an order at a customer request for a fortnight without complaint. It also runs the thinnest release-testing panel of any company in this dossier that supplies certificates at all: a purity figure, a wavelength and an appearance check.
Storefront The company sells directly at flourishglobalpeptide.net. Visit FGP → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Eight independent purity determinations, mean 97.4%, range 95.9–98.8%. The mean is a full percentage point below WXT's and the range is the second widest we track. Nothing in the results suggests a systematic problem; they suggest a company releasing on a single test and accepting the variance that follows.
The pre-dispatch photographs are more useful than they sound. Twice they let us cancel before shipping — once for a visibly under-filled vial and once for a lot where the label batch number did not match the order confirmation. Both were corrected without argument. A company that photographs its own mistakes and sends them to the customer is doing something right, even if the underlying process should have caught them.
Cold chain is the weak leg. Three of eight orders arrived without a temperature indicator and one arrived with a cold pack that had been fully liquid long enough for the outer carton to be damp. The vendor replaced it. We would not buy a solution-format product from this supplier in summer.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Eight independent purity determinations, mean 97.4% (range 95.9–98.8%).
- Pre-dispatch vial photographs supplied on 8 of 8 orders; two orders cancelled by us on the strength of them, both corrected without dispute.
- Median first response to a written enquiry: 3 hours 40 minutes across 26 logged messages.
- Chengdu incorporation date of 2019 consistent with registry records.
What we could not verify
- Any release test other than chromatographic purity and appearance. None disclosed.
- Cold-chain control — 3 of 8 orders arrived with no temperature indicator, one with a fully thawed pack and a damp carton.
- Sterility and endotoxin. Not offered.
- The identity of the synthesis house for anything outside the four molecules the company says it makes.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2025-12 | Medutest | Liraglutide 15 mg | 99.4% | 99.1% | not tested |
| 2025-10 | Janoshik | Liraglutide 10 mg | 98.3% | 97.1% | not tested |
| 2025-09 | Janoshik | Cagrilintide 20 mg | 99.2% | 98.6% | not tested |
| 2025-08 | Medutest | Liraglutide 2 mg | 99.6% | 99.4% | 82% |
| 2025-04 | VendorInvestigate | Retatrutide 20 mg | 99.1% | 98.0% | 88% |
| 2024-10 | PeptideMeter | Liraglutide 15 mg | 98.9% | 98.0% | not tested |
| 2024-04 | VendorInvestigate | Cagrilintide 10 mg | 97.9% | 97.6% | 87% |
| 2024-03 | VendorInvestigate | Retatrutide 10 mg | 99.6% | 98.6% | 90% |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and the outcome, without editorialising. 2 of 7 logged requests received a full answer within the period.
| Date | Request | Outcome |
|---|---|---|
| 2025-12 | Asked whether pre-change stock remained in distribution | Answered in full within 2 working days |
| 2025-09 | Requested the reference-standard lot number | Answered in part; the specific question was not addressed |
| 2025-05 | Asked whether sterility or endotoxin testing is performed | No response after two follow-ups |
| 2024-08 | Requested a batch record for a specific lot | Answered in full within 2 working days |
| 2024-05 | Asked for the name of the synthesis facility | Answered with a restatement of published quality claims |
| 2024-05 | Asked whether release testing is performed per lot or per campaign | Answered in part; the specific question was not addressed |
| 2024-04 | Requested comment on an independent purity determination below the stated figure | Offered a video call in place of a written answer; declined |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
Regional stock makes the difference — dispatched within the United States, day 2, cold pack still hard on arrival.
Vials wrapped individually, foam cut to fit, nothing loose in the box. Packing that has clearly been thought about.
First order, deliberately small, survodutide 5 mg only. Documentation, transit and a Medutest result at 98.5% all checked out, so the next one will not be small.
Steady supplier. Medutest results have agreed with their stated figures on every lot I have submitted.
Solid on the LL-37 5 mg. Purity where it should be, transit 3 days, paperwork in order.
Quoted 5 days, arrived in 5. Tracking updated at every hop from dispatch to door.
Shipped from their warehouse in Germany, arrived day 3, documentation complete.
Shipped with a stated storage recommendation and a shelf-life figure tied to it, without my asking.
Asked for the chromatogram instead of the summary figure and got the real trace, legible, integration visible. They send it without hesitating.
Arrived on day 4 against a quoted 4. Customs paperwork was right first time, which is why it moved that fast.
Reconstituted the MOTS-c 10 mg and it went clear on contact — no haze, no floaters, no long swirl. Tells you the lyophilisation was done properly.
Fourth order from them, all retatrutide 5 mg. Sent one vial from each to Janoshik and the whole set landed inside half a point of each other. That flatness is exactly what I pay for.
Asked a genuinely technical question about pre-dispatch storage and got a reply with numbers in it, inside 9 hours.
Identity confirmed by mass spec on the certificate, not just an area-percent figure. Both questions answered on one page.
Stock said available, stock was available, and it shipped the same day. That sequence is not as common as it should be.
Vial labels printed rather than handwritten, lot and date legible, cap seal intact on every unit.
PeptideMeter has now seen 4 of their lots through me. Not one has come back outside spec.
Cold pack was still hard on arrival in Lyon on day 4. My logger never went above 4°C across the whole run.
Pleased to find they hold stock in Canada. Domestic dispatch, day 3, no customs step at all.
Support answered on a Sunday, correctly, with the batch record attached. That is well beyond what I expected.
Submitted the GHRP-2 5 mg to VendorInvestigate blind, without telling them the source. 98.7% against a stated 98.3%. The number holds up when nobody knows whose vial it is.
Custom synthesis quote came back with a realistic timeline and they beat it. Purity on delivery matched the signed spec.
Peptide content reported at 98.5% alongside the purity figure, so I could convert straight to a working mass.
No customs paperwork, no import wait — it came from their stock in the Netherlands and arrived day 5.
Costed them per mg against three other suppliers on the same epithalon 10 mg spec. Competitive on price and clearly ahead on documentation.
Dispatched from their warehouse in Canada rather than from the factory, so the AOD-9604 5 mg was with me on day 3.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from flourishglobalpeptide.net. Visit FGP → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.